Have you recently cited evitria in your research? We say thank you – with a discount!
Since 2010, evitria’s various antibody and protein products have supported extensive life sciences researchers to explore meaningful advancements to medicine and diagnostics. Numerous, peer-reviewed publications are proof of these researchers’ accomplishments and the trust in evitria’s services to provide reliable, high-quality, and reproducible proteins and antibodies time and time again.
“We are both proud and grateful to be regularly chosen as a reliable partner in biological research, drug discovery and the development of innovative, life-changing therapies”, says Richard Park, Global Head of Client Relations & Business Development.
To further emphasize this gratitude and to promote the use of evitria’s products in research, evitria will award any research teams with a discount of up to 10% on their next order. Further details are described below.
Have a new or upcoming publication citing evitria? Claim this discount on your next order! Here’s how.
As gratitude for your trust in utilizing evitria’s products and in publishing your results, evitria is excited to extend a discount of up to 10% off of your next order with evitria. Check below to confirm your eligibility and how to claim this discount!
Check your eligibility. To be eligible for this discount,
Your research team must have published the article in the year 2023. For publications prior to 2023, please see Step 3 of Claim the discount below.
Publications may include journal publications and meeting presentations.
Claim the discount
Reach out to rp@evitria.com and reference “Publication discount” in the subject of your email. Emails must be received by Dec 31, 2023.
Include a PDF version of the publication as a link or an attachment to the email.
For all inquiries for publications prior to 2023, include the year of publication in the body of the email, and we will confirm whether your team will be able to claim this discount!
Within 1 business day, you will receive confirmation of your discount, along with important notes on its value and how it can be applied to your future order.
Poster Download: antibody development and quality control by mass spectometry
evitria productions show consistent glycan profiles between batches. These profiles are in agreement with commercially available (GMP) antibodies.
Glycan analysis by LC-MS can verify glycan modifications, such as afucosylation, to provide further quality assurance.
The production of high quality, reproducible material is critical for the development of antibody-based therapeutics. The evitria-Genovis workflow combines rapid, high quality, antibody production with high-throughput mass spectrometry for greater insight and control of key quality attributes.
Bespoke solutions for lead selection and optimization in cancer antibody research
High quality research. Fast timelines. Within budget. You’re often allowed two out of the three, but what if you could have all three?
A trusted CRO with flexible workflows provides a reliable and supportive structure to build out preclinical research. Over 120,000 successful antibody production runs and a 13+ year history allows evitria AG to help teams rapidly complete preclinical work and use that data to advance.
